Influence of Deposition Temperature on Cu-BDC Surface-Anchored Metal-Organic Framework Formation.

Surface-anchored metal-organic frameworks (surMOFs) are crystalline, nanoporous, supramolecular materials mounted to substrates that have the potential for integration within device architectures relevant for a variety of electronic, photonic, sensing, and gas storage applications. This research investigates the thin film formation of the Cu-BDC (copper benzene-1,4-dicarboxylate) MOF system on a carboxylic acid-terminated self-assembled monolayer by alternating deposition of solution-phase inorganic and organic precursors. X-ray diffraction (XRD) and atomic force microscopy (AFM) characterization demonstrate that crystalline Cu-BDC thin films are formed via Volmer-Weber growth.

Safety testing of Ovaprene: An investigational nonhormonal monthly vaginal contraceptive.

Objectives: Evaluate the safety of Ovaprene, an investigational nonhormonal vaginal contraceptive designed for monthly use.

Study Design: Open-label, multicenter study enrolling heterosexually-active women with previous permanent contraception who underwent assessments during five menstrual cycles: baseline postcoital test cycle, diaphragm postcoital test cycle, Ovaprene safety cycle, and two Ovaprene postcoital test cycles. Safety outcomes included treatment-emergent adverse events, systemic laboratory findings, pelvic examinations, colposcopies, Nugent scores, determination of community state types of vaginal microbiota, and anti-Escherichia coli activity and inflammatory markers in cervicovaginal fluids.

Successful postcoital testing of Ovaprene: An investigational non-hormonal monthly vaginal contraceptive.

Objective: Evaluate reduction in progressively motile sperm per high power field (HPF) in midcycle cervical mucus after intercourse with Ovaprene: an investigational monthly non-hormonal vaginal contraceptive consisting of a vaginal ring and mechanical barrier, releasing spermiostatic ferrous gluconate.

Study Design: Open-label, multicenter study enrolling heterosexually-active women with previous permanent contraception. Participants underwent a baseline postcoital test cycle with no device to confirm the presence of sperm, followed by one diaphragm postcoital test cycle, one Ovaprene safety cycle, and two Ovaprene postcoital test cycles.

A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women.

Objectives: The exploratory objectives of this study were to evaluate the usability and acceptability and to conduct a preliminary evaluation of the efficacy of DARE-HRT1. DARE-HRT1 is an intravaginal ring (IVR) that releases 17β2-estradiol (E2) with progesterone (P4) over 28 days. It is the first combination E2 and P4 IVR being developed for the treatment of vasomotor symptoms (VMS) in healthy postmenopausal women with an intact uterus.